MedTrace Logo

A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated

NCT04863638 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4400

Last updated 2023-06-18

No results posted yet for this study

Summary

This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged 18-59 years old with 2-dose schedule. And subjects in the same age are randomly assigned to different immunization schedule groups.

Conditions

  • Covid19

Interventions

BIOLOGICAL

3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated

the schedule of Day 0, 21, 42

BIOLOGICAL

3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated

the schedule of Day 0, 21, 111

BIOLOGICAL

3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated

the schedule of Day 0, 21, 171

BIOLOGICAL

2 doses of vaccine

the schedule of Day 0, 21

Sponsors & Collaborators

  • Beijing Institute of Biological Products Co Ltd.

    collaborator INDUSTRY

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Yanxia Wang, Bachelor · Henan Provincial Center for Disease Control and Prevention

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2021-12-20
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04863638 on ClinicalTrials.gov